Abstract 124P
Background
Carcinoma esophagus is a disease with dismal prognosis and even though treatment has evolved considerably, morbidity after surgery has remained a drawback. We intend to prospectively study the pattern of care for such patients at our centre, how it affects their subsequent quality of life (QoL) and the factors that influence these changes.
Methods
All patients who underwent curative esophagectomy for carcinoma esophagus from May,2017 to May,2019 were included in the study after obtaining informed consent. Patient characteristics, pre-op therapy, surgical details and final histopathology reports were collected. QoL was collected at pre-op, 1 and 6 months after surgery using FACT-E, OES 18 and OG 25 questionnaires. QoL analysis was done comparing the changes that occured after curative surgery with the baseline value.
Results
99 patients underwent curative esophagectomy during the study period. With a mean age of 58.8 and a male to female ratio of 3.54 : 1, 84/99 underwent surgery after NACT. Lower third and GE junction primary adenocarcinomas accounted for 72 % of cases. Totally minimally invasive McKeowns procedure was the most common surgery done (33%). 8 patients comprised the 30-day mortality with 5 patients having anastomotic leak. QoL analysis showed a dip in post-op QoL at 1 month, with improvement to baseline at 6 months, both in general functional scales, as well as symptom scales. The improvement in symptom scales assessed by OES 18 and OG 25 were found to be statistically significant ( p value < 0.05). Younger patients (<50 yrs) and females fared better during the post-op period. There was a trend to better QoL for patients who underwent minimally invasive procedures. Those patients who had post-op complications, had inferior QoL at 1 month, but later improved by 6 months.
Conclusions
Radical esophagectomy can be performed with achievable morbidity and mortality at high volume centres. Global HRQoL scores show a dip during immediate post-surgery period, but then picks up to even eclipse pre-op values. Post-op morbidity, as expected, adversely affects HRQoL, but once patients tide over the immediate period, they often do well as time passes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session